Blood Biomarker in Early Parkinson's Disease

Completed

Conditions studied: Parkinson Disease

In brief

Currently, there are no cures or disease modifying therapies for Parkinson's disease (PD). This is partially due to the inability to detect the disease before it has progressed to a stage where there are clinical manifestations. The identification and validation of high throughput biomarkers to measure disease progression (as well as identify pre-clinical disease onset) is critical to the development of disease-modifying or even preventative therapies. In this study, we are testing a blood biomarker for PD. Several detection parameters will be assessed through enrollment of Parkinson's patients and age matched healthy volunteers over 50 years of age to learn more about the analytical process and biological variability.

Key facts

Study ID

NCT03384797

Run by

Duke University

People needed

65

Starts

2018-01-22

Expected to finish

2019-01-07

Last updated by the study team

2019-06-10

Who can join

Age: 50 and older. Sex: any. Healthy volunteers: accepted.

You may not qualify if…

• Parkinson's Disease Patients:
• Known additional neurological disease
• Clinical trial intervention within the last 6 months
• Healthy Control Participants:
• Neurological degenerative diseases (such as Parkinson's, Alzheimer's or Huntington's)
• Clinical trial intervention within the last 6 months

Where it is running

• Duke University Medical Facility — Durham, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.